← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Vascular Vision Pharmaceuticals Company
Wynantskill, NY
$4,150,441
Total funding
8
Grants
Funding over time
peak $1M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,150,441 · 8
By mechanism
R44$3,058,782 · 1
R41$502,714 · 3
R43$300,000 · 3
N01$288,945 · 1
Investigators at Vascular Vision Pharmaceuticals Company
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Sulfated Non-Anticoagulant Heparin Nanoparticle (VVP728) for Sickle Cell Disease Management$1,031,733
R44 · FY2024 · HL
Sulfated Non-Anticoagulant Heparin Nanoparticle (VVP728) for Sickle Cell Disease Management$1,030,837
R44 · FY2023 · HL
Sulfated Non-Anticoagulant Heparin Nanoparticle (VVP728) for Sickle Cell Disease Management$996,212
R44 · FY2022 · HL
IGF::OT::IGF Topic 374 Phase 1 - Topical Delivery of Nanoformulated Natural Bioactive Chemopreventive Agent in Skin Cancer. September 17, 2018 - June 16, 2019. CAN#8478358$288,945
N01 · FY2018 · CA
Multi-Modal Mechanisms of Novel Sulfated Non Anticoagulant Heparin inSickle Cell Disease Management$215,058
R41 · FY2019 · HL
Enabling high dose regional chemotherapy while minimizing systemic toxicity$159,306
R41 · FY2010 · CA
Nanoparticle targeting of cathepsin-L inhibitor and doxorubicin in breast cancer$128,350
R41 · FY2007 · CA
Enhancing tumor uptake of chemotherapeutics by novel heparin-derived compounds$100,000
R43 · FY2006 · CA
Tissue Factor/Vlla modulation in Ocular angiogenesis$100,000
R43 · FY2006 · EY
kininiogen in Ocular angiogenesis-mediated disorders$100,000
R43 · FY2005 · EY